CALT vs. NGNE, NUVB, MLYS, SLN, SLRN, OLMA, PHAT, CVAC, COGT, and NRIX
Should you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Neurogene (NGNE), Nuvation Bio (NUVB), Mineralys Therapeutics (MLYS), Silence Therapeutics (SLN), Acelyrin (SLRN), Olema Pharmaceuticals (OLMA), Phathom Pharmaceuticals (PHAT), CureVac (CVAC), Cogent Biosciences (COGT), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical preparations" industry.
Neurogene (NASDAQ:NGNE) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, community ranking, institutional ownership and dividends.
Calliditas Therapeutics AB (publ) received 19 more outperform votes than Neurogene when rated by MarketBeat users. However, 100.00% of users gave Neurogene an outperform vote while only 60.47% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
Neurogene has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
Neurogene has a net margin of 0.00% compared to Neurogene's net margin of -38.72%. Calliditas Therapeutics AB (publ)'s return on equity of -31.17% beat Neurogene's return on equity.
Neurogene has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.
Neurogene currently has a consensus target price of $49.00, indicating a potential downside of 3.73%. Calliditas Therapeutics AB (publ) has a consensus target price of $34.00, indicating a potential upside of 61.83%. Given Neurogene's higher possible upside, analysts clearly believe Calliditas Therapeutics AB (publ) is more favorable than Neurogene.
52.4% of Neurogene shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 1.6% of Neurogene shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Neurogene had 5 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 9 mentions for Neurogene and 4 mentions for Calliditas Therapeutics AB (publ). Neurogene's average media sentiment score of 0.48 beat Calliditas Therapeutics AB (publ)'s score of 0.33 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the news media.
Summary
Neurogene beats Calliditas Therapeutics AB (publ) on 10 of the 17 factors compared between the two stocks.
Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically
Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Calliditas Therapeutics AB (publ) Competitors List
Related Companies and Tools